These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29568395)

  • 1. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
    Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
    Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 3. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 4. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
    Yan SB; Um SL; Peek VL; Stephens JR; Zeng W; Konicek BW; Liu L; Manro JR; Wacheck V; Walgren RA
    Invest New Drugs; 2018 Aug; 36(4):536-544. PubMed ID: 29188469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
    Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S
    Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy.
    Vanoli F; Herviou L; Tsuda Y; Sung P; Xie Z; Fishinevich E; Min SS; Mallen W; de Wardin HT; Zhang Y; Jasin M; Antonescu CR
    Oncogenesis; 2023 Feb; 12(1):8. PubMed ID: 36801905
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Pekova B; Sykorova V; Mastnikova K; Vaclavikova E; Moravcova J; Vlcek P; Lastuvka P; Taudy M; Katra R; Bavor P; Kodetova D; Chovanec M; Drozenova J; Astl J; Hrabal P; Vcelak J; Bendlova B
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs.
    Cho H; Kim N; Murakami T; Sim T
    Front Oncol; 2021; 11():757598. PubMed ID: 34790577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
    Rabban JT; Devine WP; Sangoi AR; Poder L; Alvarez E; Davis JL; Rudzinski E; Garg K; Bean GR
    Histopathology; 2020 Jul; 77(1):100-111. PubMed ID: 31971278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
    Kummar S; Lassen UN
    Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
    Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
    Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
    Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
    Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
    JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y; Matsumoto M; Takano N; Hirao M; Matsuda K; Tozuka T; Onda N; Nakamichi S; Takeuchi S; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Med; 2024 Jun; 13(12):e7393. PubMed ID: 38923428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.
    Passiglia F; Caparica R; Giovannetti E; Giallombardo M; Listi A; Diana P; Cirrincione G; Caglevic C; Raez LE; Russo A; Rolfo C
    Expert Opin Investig Drugs; 2016; 25(4):385-92. PubMed ID: 26881293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.